These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 2498026

  • 1. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide.
    Mikus G, Gross AS, Beckmann J, Hertrampf R, Gundert-Remy U, Eichelbaum M.
    Clin Pharmacol Ther; 1989 May; 45(5):562-7. PubMed ID: 2498026
    [Abstract] [Full Text] [Related]

  • 2. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.
    Gross AS, Mikus G, Fischer C, Hertrampf R, Gundert-Remy U, Eichelbaum M.
    Br J Clin Pharmacol; 1989 Nov; 28(5):555-66. PubMed ID: 2511912
    [Abstract] [Full Text] [Related]

  • 3. Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.
    Gross AS, Mikus G, Fischer C, Eichelbaum M.
    Eur J Clin Pharmacol; 1991 Nov; 40(2):155-62. PubMed ID: 1906003
    [Abstract] [Full Text] [Related]

  • 4. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.
    Gross AS, Phillips AC, Rieutord A, Shenfield GM.
    Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
    Brøsen K, Gram LF.
    Eur J Clin Pharmacol; 1989 Apr; 36(6):537-47. PubMed ID: 2570698
    [Abstract] [Full Text] [Related]

  • 8. Debrisoquin oxidation polymorphism in a Spanish population.
    Benítez J, LLerena A, Cobaleda J.
    Clin Pharmacol Ther; 1988 Jul; 44(1):74-7. PubMed ID: 3391005
    [Abstract] [Full Text] [Related]

  • 9. Influence of debrisoquin phenotype on the inducibility of propranolol metabolism.
    Shaheen O, Biollaz J, Koshakji RP, Wilkinson GR, Wood AJ.
    Clin Pharmacol Ther; 1989 Apr; 45(4):439-43. PubMed ID: 2702801
    [Abstract] [Full Text] [Related]

  • 10. CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis.
    Doki K, Homma M, Kuga K, Aonuma K, Kohda Y.
    Pharmacogenet Genomics; 2012 Nov; 22(11):777-83. PubMed ID: 22941032
    [Abstract] [Full Text] [Related]

  • 11. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin.
    Roy SD, Hawes EM, McKay G, Korchinski ED, Midha KK.
    Clin Pharmacol Ther; 1985 Aug; 38(2):128-33. PubMed ID: 4017414
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M.
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.